- Molecular NameNebivolol
- Synonymnebivolol; Nebivololum [latin]
- Weight405.441
- Drugbank_IDDB04861
- ACS_NO99200-09-6
- Show 3D model
- LogP (experiment)4.04
- LogP (predicted, AB/LogP v2.0)3.81
- pka8.22
- LogD (pH=7, predicted)2.6
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-3.33
- LogSw (predicted, AB/LogsW2.0)0.65
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors3
- No.of HBond Acceptors5
- No.of Rotatable Bonds6
- TPSA70.95
- StatusFDA approved
- AdministrationN/A
- PharmacologyA β1 receptor blocker with nitric oxide-potentiating vasodilatory effect used in treatment of hypertension and, in Europe, also for left ventricular failure.[
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability50.0
- Protein binding98.0
- Volume of distribution (VD)10.1 to 39.4 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmNebivolol is extensively metabolised, partly to active hydroxy-metabolites. The metabolism by aromatic hydroxylation is subject to the CYP2D6 dependent genetic oxidative polymorphism.
- Half life8 (fast metabolisers) to 27 (slow metabolisers) h.
- ExcretionRenal and fecal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe most frequent adverse events (incidence between 1-10%) are headache, dizziness, tiredness and paraesthesia
- LD50 (rat)N/A
- LD50 (mouse)N/A